RFK’s Peptide Ruling: Where Things Stand in April 2026

In February 2026, HHS Secretary Robert F. Kennedy Jr. said on the Joe Rogan Experience that approximately 14 of the 19 peptides placed on the FDA’s Category 2 restricted list in 2023 would be moved back to Category 1. Category 1 is titled “Bulk Drug Substances Under Evaluation” — a stage in the nomination review, not authorisation to compound. A substance becomes compoundable under section 503A only once the FDA places it on the 503A Bulks List, which takes a final rule.

It was the biggest shift in peptide regulation in years. But as of April 2026, the formal FDA reclassification has not been published. Here’s where things actually stand.

What RFK Announced

On February 27, 2026, Kennedy stated that the FDA would move roughly 14 of the 19 restricted peptides back to Category 1 status. He framed that as restoring pharmacies’ ability to prepare them; Category 1 itself does not do that, being the FDA’s “under evaluation” stage rather than a permission. The announcement generated widespread coverage and significant optimism across the peptide research community.

The peptides named in the coverage that followed include BPC-157, TB-500, Thymosin Alpha-1, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, GHK-Cu, and several others pulled from compounding pharmacy shelves in 2023. None of them has since been placed on the 503A Bulks List.

What Hasn’t Happened Yet

The announcement was a statement of intent — not a regulatory action. Moving a substance into Category 1 only puts it under evaluation; for a pharmacy to compound it under section 503A, the FDA has to place it on the 503A Bulks List through a final rule. Neither step has been completed for these peptides.

Compounding pharmacies are in a holding pattern. Many are preparing to resume peptide compounding as soon as written guidance is issued, but most are waiting for explicit FDA clearance before filling orders. Until the formal list is published, the Category 2 designations remain in effect.

It is also important to understand what reclassification does and does not mean. FDA’s Category 1 is titled “Bulk Drug Substances Under Evaluation” — it is an interim status carrying enforcement discretion while the agency assesses a nomination, not authorisation to compound and not FDA approval. Placement on the 503A Bulks List is a separate step requiring a final rule. Compounded peptides would still require a valid prescription, still lack formal FDA approval as finished drug products, and still carry no standardized dosing guidelines.

Why the Delay Matters

The gray market fills the gap. Since the 2023 restrictions, researchers have largely turned to vendors selling peptides labeled “for research use only” — the category that Prof. Peptide’s vetted vendor network operates in. Demand has not decreased; it simply moved outside the compounding pharmacy system.

When the formal reclassification does arrive, compounding pharmacies will need time to source pharmaceutical-grade ingredients and ramp up production. Industry groups have warned that even after a formal announcement, supply through compounding channels may take weeks or months to stabilize.

What to Watch For

The FDA’s bulk drug substance documents are what to watch, and there are two of them. The nomination list shows which substances sit in Category 1 under evaluation; a final rule placing a substance on the 503A Bulks List is what would actually let a pharmacy compound it. As of this update no peptide from the 19 has reached the second.

Prof. Peptide will update this article as developments occur.